Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Microarray-based diagnostic test has reached level 3 in evidence-based medicine
December 28th, 2004
Agendia, a genomics company based in Amsterdam, the Netherlands, collaborating with the TRANSBIG translational research network, announced at the San Antonio Breast Cancer conference that the 70-gene expression signature (MammaPrint) outperformed all currently used standard diagnostic criteria in predicting future development of distant metastases (the development of tumors in other parts of the body) and overall survival in a large breast cancer study. The international validation project was led by TRANSBIG. The data analysis was carried out independently by a statistical team in Belgium. The TRANSBIG consortium intends to use the MammaPrint test...
Source: Cancer Weekly (2004-12-28)
|
